Welcome to our dedicated page for Cumberland Pharmaceuticals SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cumberland Pharmaceuticals Inc. (CPIX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of its financial reporting and material events. As a Nasdaq-listed specialty pharmaceutical company, Cumberland uses these filings to report on its commercial portfolio of FDA-approved brands, clinical programs, and corporate transactions.
Investors can use this page to access annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include discussions of net revenues by product, research and development spending, liquidity, and risk factors relevant to Cumberland’s hospital acute care, gastroenterology, and oncology businesses. These filings also describe the performance of key brands such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia, along with updates on Phase II ifetroban studies in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Pulmonary Fibrosis.
The page also lists current reports on Form 8-K, where Cumberland discloses significant events. Recent 8-Ks reference quarterly financial results, strategic arrangements with RedHill Biopharma to jointly commercialize Talicia, and amendments to a revolving credit facility with Pinnacle Bank that outline borrowing capacity, collateral, and covenant terms.
Users can review proxy statements and other governance-related documents to understand board matters and executive compensation, as well as Form 4 insider transaction reports that detail purchases and sales of CPIX shares by officers, directors, and major shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify important changes in revenue composition, credit arrangements, clinical program disclosures, and other material information. Real-time updates from EDGAR ensure that new Cumberland filings, including 10-K, 10-Q, 8-K, and Form 4 reports, are added as they become available.
Cumberland Pharmaceuticals Inc. reported the results of its annual shareholder meeting held in Nashville, Tennessee on April 21, 2026. Shareholders elected Class I directors Kenneth J. Krogulski and Caroline R. Young, each receiving over 98% of votes cast, with Krogulski supported by 9,561,336 votes and Young by 9,479,023 votes.
Shareholders also ratified the appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for the year ending December 31, 2026, with 12,714,116 votes in favor. An advisory vote approved the compensation of named executive officers, and another advisory vote indicated a strong preference to hold this say‑on‑pay vote every three years, supported by 7,844,848 votes.
Cumberland Pharmaceuticals agreed to sell the assets tied to its U.S. branded commercial products to an Apotex affiliate for $100,000,000 in cash at closing under an Asset Purchase Agreement. The assets include Cumberland’s FDA‑approved brands such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol and Vibativ, plus certain product-related equity interests.
Cumberland will retain its ifetroban pipeline programs and majority stake in Cumberland Emerging Technologies and plans to focus on these orphan and specialty development candidates after closing. The deal requires approval by holders of a majority of outstanding shares and other customary conditions, with a long-stop date of August 20, 2026.
Both parties agreed to $4,000,000 termination fees in specified circumstances, as well as non‑solicitation, non‑competition and non‑interference covenants for up to four years. Voting and support agreements cover about 41% of outstanding shares, and a financial advisor delivered a fairness opinion stating the consideration is fair and reasonable from a financial point of view.
Cumberland Pharmaceuticals director Martin S. Brown Jr. received a grant of 1,800 shares of Common Stock at $2.80 per share. This award increased his direct holdings to 10,300 shares. The transaction is coded as a grant or award acquisition, indicating compensation rather than an open-market purchase.
Galante Joseph C reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals director Joseph C. Galante received a grant of 1,800 shares of Common Stock at $2.80 per share. This award increases his directly held stake to 63,656 shares. The transaction is classified as a grant or award, not an open-market purchase.
Jones James reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals director James Jones received a stock grant as part of his compensation. He was awarded 1,800 shares of Common Stock at a value of $2.80 per share. Following this grant, he directly owns 46,863 shares, indicating a routine, compensation-related increase in his holdings.
Cumberland Pharmaceuticals director Kenneth Krogulski received stock awards totaling 5,800 shares of common stock. The grants were recorded at a price of $2.80 per share on March 18, 2026. Following these award acquisitions, he directly holds 302,338 shares of Cumberland Pharmaceuticals common stock.
Cumberland Pharmaceuticals director Caroline Young received a grant of 1,800 shares of Common Stock of CUMBERLAND PHARMACEUTICALS INC. The shares were awarded at a price of $2.80 per share. Following this compensation-related acquisition, she directly holds 35,109 shares of the company’s common stock.
Cumberland Pharmaceuticals vice president receives new stock options grant. Vice President of Organizational Development Anthony Todd M. was granted options to acquire 3,000 shares of Cumberland Pharmaceuticals common stock at an exercise price of $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 18, 2036. Following this award, his reported derivative holdings total 21,000 options.
Bitterman Chris T. reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals vice president of sales and marketing Chris T. Bitterman received a grant of options to buy 3,000 shares of common stock at $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 16, 2036. Following this award, he holds options covering 19,000 shares in total.
Cumberland Pharmaceuticals Vice President and Chief Financial Officer John M. Hamm received a grant of 3,000 stock options on March 18, 2026. These options carry an exercise price of $2.80 per share and expire on March 18, 2036, bringing his reported option holdings to 18,250 shares.